Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAPAS: tPA and C3F8 for Submacular Haemorrhage in Wet AMD
NCT01835067Phase 3Completed
- Sponsor
- King's College Hospital
- Start
- Sep 2014
- Primary completion
- Nov 2019
- Modality
- rProtein (Recombinant Protein), Biologic, GAS (Genetic analysis systems)
- Countries
- 1
01
Overview
A Phase 3 trial of tissue-plasminogen activator, perflutren in submacular hemorrhage (SMH), sponsored by King's College Hospital. Started Sep 2014; status: completed.
02
Drugs
tissue-plasminogen activatorperflutren
03
Conditions
submacular hemorrhage (SMH)
Beyond the preview
Go deeper on NCT01835067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01835067.